Human/Cynomolgus Monkey PD-L1/B7-H1 Quantikine ELISA Kit

• Reactivity: Hu, Pm-Cm
• Applications: ELISA
• Conjugate: HRP

Human/Cynomolgus Monkey PD-L1/B7-H1 Quantikine ELISA Kit Summary

• Background: The Quantikine^® Human/Cynomolgus Monkey B7-H1/PD-L1 Immunoassay is a 4.5 hour solid-phase ELISA designed to measure human/cynomolgus monkey B7-H1 in cell culture supernates, cell lysates, serum, plasma, and urine. It contains HEK293-expressed recombinant human B7-H1/PD-L1 and has been shown to accurately quantitate the recombinant factor. Results obtained using natural human/cyno...molgus monkey B7-H1/PD-L1 showed linear curves that were parallel to the standard curves obtained using the Quantikine® kit standards. These results indicate that this kit can be used to determine relative mass values for naturally occurring human/cynomolgus monkey B7-H1/PD-L1.
  Read this White Paper on detecting B7-H1/PD-L1 levels in multiple cancer subtypes.
  Show More
• Specificity: Natural and recombinant human B7-H1/PD-L1. This assay also recognizes natural cynomolgus monkey B7-H1/PD-L1.
• Source: N/A
• Inter-Assay: See PDF Datasheet for details
• Intra-Assay: See PDF Datasheet for details
• Spike Recovery: See PDF Datasheet for details
• Sample Volume: See PDF Datasheet for details

Applications/Dilutions

• Dilutions:
  • ELISA
• Application Notes: No significant interference observed with available related molecules.

Packaging, Storage & Formulations

• Storage: Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Human/Cynomolgus Monkey PD-L1/B7-H1 Quantikine ELISA Kit

• Avelumab
• B7-H
• B7H1
• B7-H1
• B7H1PDCD1L1
• CD274 antigenMGC142294
• CD274 molecule
• CD274
• PDCD1L1
• PDCD1LG1
• PDCD1LG1MGC142296
• PDL1
• PD-L1
• PD-L1B7 homolog 1
• PDL1PDCD1 ligand 1
• programmed cell death 1 ligand 1
• Programmed death ligand 1

Background

PD-L1, also known as B7-H1 and CD274, is an approximately 65 kDa transmembrane glycoprotein in the B7 family of immune regulatory molecules. PD-L1 is expressed on inflammatory-activated immune cells including macrophages, T cells, and B cells, keratinocytes, enothelial and intestinal epithelial cells, as well as a variety of carcinomas and melanoma. PD-L1 binds to T cell B7-1/CD80 and PD-1. It suppresses T cell activation and proliferation and induces the apoptosis of activated T cells. It plays a role in the development of immune tolerance by promoting T cell anergy and enhancing regulatory T cell development. PD-L1 favors the development of anti-inflammatory IL-10 and IL-22 producing dendritic cells and inhibits the development of Th17 cells. In cancer, PD-L1 provides resistance to T cell mediated lysis, enhances EMT, and enhances the tumorigenic function of Th22 cells.

⚠ WARNING: This product can expose you to chemicals including N,N-Dimethylforamide, which is known to the State of California to cause cancer. For more information, go to www.P65Warnings.ca.gov.

Publications for PD-L1 (DB7H10)(21)

Publications using DB7H10

• Yuan, Q;Fan, Z;Huang, W;Huo, X;Yang, X;Ran, Y;Chen, J;Li, H; Human cytomegalovirus UL23 exploits PD-L1 inhibitory signaling pathway to evade T cell-mediated cytotoxicity mBio 2024-06-03 [PMID: 38829126] (Human)
• Eslami-S Z, Cortés-Hernández LE, Sinoquet L et al. Circulating tumour cells and PD-L1-positive small extracellular vesicles: the liquid biopsy combination for prognostic information in patients with metastatic non-small cell lung cancer British journal of cancer 2023-11-16 [PMID: 37973956] (Human)
• Király, Z;Nagy, E;Bokor, L;Kovács, A;Marschalkó, M;Hidvégi, B; The Possible Clinical Significance of a Decreased Serum Level of Soluble PD-L1 in Discoid Lupus Erythematosus, but Not in Subacute Cutaneous Lupus Erythematosus-A Pilot Study Journal of clinical medicine 2023-08-30 [PMID: 37685714] (Human)
• L Zhang, H Li, J Liu, G Sun, X Tang, S Xu, L Zhang, W Zhang, B Ai The screening of compounds regulating PD-L1 transcriptional activity in a cell functional high-throughput manner Cancer Medicine, 2023-03-25;0(0):. 2023-03-25 [PMID: 36965083] (Human)
• J Ma, Q Zhou, W Xu, C Li, H Wang, Z Zhai, Y Zhang, W Wahafu Urine PD-L1 is a tumor tissue candidate substitute and is associated with poor survival in muscle-invasive bladder cancer patients International immunopharmacology, 2022-12-15;114(0):109535. 2022-12-15 [PMID: 36527880] (Human)
• Á Széles, PT Kovács, A Csizmarik, M Váradi, P Riesz, T Fazekas, S Váncsa, P Hegyi, C Oláh, S Tschirdewa, C Darr, U Krafft, V Grünwald, B Hadaschik, O Horváth, P Nyirády, T Szarvas High Pretreatment Serum PD-L1 Levels Are Associated with Muscle Invasion and Shorter Survival in Upper Tract Urothelial Carcinoma Biomedicines, 2022-10-13;10(10):. 2022-10-13 [PMID: 36289821] (Human)
• O Munoz, R Banga, R Schelling, FA Procopio, A Mastrangel, P Nortier, K Ohmiti, J Daraspe, M Cavassini, C Fenwick, L Perez, M Perreau Active PD-L1 incorporation within HIV virions functionally impairs T follicular helper cells PloS Pathogens, 2022-07-05;18(7):e1010673. 2022-07-05 [PMID: 35788752] (Human)
• L Chavez-Gal, A Ruiz, K Martinez-E, H Aguilar-Du, M Torres, R Falfan-Val, G Pérez-Rubi, M Selman, I Buendia-Ro Circulating Levels of PD-L1, TIM-3 and MMP-7 Are Promising Biomarkers to Differentiate COVID-19 Patients That Require Invasive Mechanical Ventilation Biomolecules, 2022-03-14;12(3):. 2022-03-14 [PMID: 35327637] (Human)
• K Nakano, K Yokoyama, S Shin, K Uchida, K Tsuji, M Tanaka, K Uchimaru, T Watanabe Exploring New Functional Aspects of HTLV-1 RNA-Binding Protein Rex: How Does Rex Control Viral Replication? Viruses, 2022-02-16;14(2):. 2022-02-16 [PMID: 35216000] (Human)
• A Vikerfors, S Davidsson, J Frey, T Jerlström, J Carlsson Soluble PD-L1 in Serum and Urine in Urinary Bladder Cancer Patients Cancer, 2021-11-21;13(22):. 2021-11-21 [PMID: 34830993] (Human)
• CP Mao, SC Wang, YP Su, SH Tseng, L He, AA Wu, RBS Roden, J Xiao, CF Hung Protein detection in blood with single-molecule imaging Science Advances, 2021-08-11;7(33):. 2021-08-11 [PMID: 34380620] (Human)
• G Tosev, W Wahafu, P Reimold, I Damgov, C Schwab, C Aksoy, A Kaczorowsk, A Stenzinger, J Nyarangi-D, M Hohenfelln, S Duensing Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder Scientific Reports, 2021-07-09;11(1):14244. 2021-07-09 [PMID: 34244564] (Human)
• T Mocan, M Ilies, I Nenu, R Craciun, A Horhat, R Susa, I Minciuna, I Rusu, LP Mocan, A Seicean, CA Iuga, NA Hajjar, M Sparchez, DC Leucuta, Z Sparchez Serum levels of soluble programmed death-ligand 1 (sPD-L1): A possible biomarker in predicting post-treatment outcomes in patients with early hepatocellular carcinoma International immunopharmacology, 2021-02-18;94(0):107467. 2021-02-18 [PMID: 33611059] (Human)
• J Xu, J Wang, X Wang, R Tan, X Qi, Z Liu, H Qu, T Pan, Q Zhan, Y Zuo, W Yang, J Liu Soluble PD-L1 improved direct ARDS by reducing monocyte-derived macrophages Cell Death Dis, 2020-10-30;11(10):934. 2020-10-30 [PMID: 33127884] (Human)
• Y Fei, J Yu, Y Li, L Li, S Zhou, T Zhang, L Li, L Qiu, B Meng, Y Pan, X Ren, Z Qian, X Wang, H Zhang Plasma soluble PD-L1 and STAT3 predict the prognosis in diffuse large B cell lymphoma patients J Cancer, 2020-10-17;11(23):7001-7008. 2020-10-17 [PMID: 33123290] (Human)
• L Cui, SY Chen, T Lerbs, JW Lee, P Domizi, S Gordon, YH Kim, G Nolan, P Betancur, G Wernig Activation of JUN in fibroblasts promotes pro-fibrotic programme and modulates protective immunity Nat Commun, 2020-06-03;11(1):2795. 2020-06-03 [PMID: 32493933] (Human)
• A Castello, S Rossi, L Toschi, L Mansi, E Lopci Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors and Its Correlation with Metabolic Parameters Cancers (Basel), 2020-05-27;12(6):. 2020-05-27 [PMID: 32471030] (Human)
• C Chiarucci, S Cannito, MG Daffinà, G Amato, G Giacobini, O Cutaia, MF Lofiego, C Fazio, D Giannarell, R Danielli, AM Di Giacomo, S Coral, L Calabrò, M Maio, A Covre Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival Cancers (Basel), 2020-02-05;12(2):. 2020-02-05 [PMID: 32033266] (Human)
• J Yang, G Hu Significance of PD-L1 in the diagnosis and treatment of B-cell malignant lymphoma Oncol Lett, 2019-01-28;17(3):3382-3386. 2019-01-28 [PMID: 30867773] (Human)
• J Jin, J Si, Y Liu, H Wang, R Ni, J Wang Elevated serum soluble programmed cell death ligand 1 concentration as a potential marker for poor prognosis in small cell lung cancer patients with chemotherapy Respir. Res., 2018-10-05;19(1):197. 2018-10-05 [PMID: 30290817] (Human)
• HJ Kim, S Park, KJ Kim, J Seong Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy Radiother Oncol, 2018-01-30;0(0):. 2018-01-30 [PMID: 29366520] (Human)